Notwithstanding positive clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable opposition from managed care entities. These companies are frequently creating barriers to reimbursement, including steep expense criteria and PA that hinder consumer availability. Market indic